ACTRN12615000114549已完成未知
Overweight or obese adults, participating in a 12-week habit-based intervention (Ten Top Tips or Do Something Different) or wait list to achieve weight loss maintenance 12-months after the intervention.
Gina Cleo0 个研究点目标入组 75 人开始时间: 2015年2月10日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 75 Years（—）
- 性别
- All
入选标准
- •Obese or overweight by BMI classification (equal or greater than 25.0kg/m2)
- •Able to consent for themselves
- •Able to speak English
- •Live on the Gold Coast, QLD
- •Able to access their email and/or phone every day
- •Able to exercise
排除标准
- •Participating in other weight management programs or taking any medications which affect appetite, metabolism or weight
- •Unable to provide consent due to mental incapacity
- •Significantly ill
- •220kg or over
研究者
相似试验
招募中
不适用
The effects of intermittent fasting and high intensity interval training on body composition, markers of metabolic and cardiovascular health and micro ribonucleic acid (miRNA) expression in overweight/obese individualsMetabolic SyndromeDiet and Nutrition - ObesityMetabolic and Endocrine - Metabolic disordersObesityACTRN12615001331527Victoria University260
尚未招募
不适用
Intensive Early Adaptive Therapy (I-EAT) to Improve Feeding and Swallowing: A Clinical Trial for Infants at Risk of Cerebral Palsy.cerebral palsydysphagiaACTRN12618000305224The University of Sydney70
进行中（未招募）
不适用
A 12-month, two-armed, randomized, double-masked, multicenter, Phase IIIb study assessing the efficacy and safety of laser photocoagulation as adjunctive to Ranibizumab intravitreal injections vs. laser photocoagulation monotherapy in patients with visual impairment due to diabetic macular edema followed by a 12 month follow up period - RELATIOdiabetic macular edemaMedDRA version: 12.1Level: LLTClassification code 10057934Term: Diabetic macular edemaEUCTR2010-018852-29-DEovartis Pharma GmbH
已完成
不适用
Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.-N329 Bladder disorder, unspecifiedBladder disorder, unspecifiedN329PER-078-08PFIZER S.A.,
已完成
不适用
Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)-N328 Other specified disorders of bladderOther specified disorders of bladderN328PER-035-07PFIZER S.A.,